Price (delayed)
$1.28
Market cap
$50.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.76
Enterprise value
$93.79M
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique
There are no recent dividends present for BCEL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.